Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.

CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther. 2013 Jul; 12(7):1171-9.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.